Antibiotic Resistance Prevalence and Trends in Patients Infected with in the Period 2013-2020: Results of the European Registry on Management (Hp-EuReg)
Overview
Authors
Affiliations
Bacterial antibiotic resistance changes over time depending on multiple factors; therefore, it is essential to monitor the susceptibility trends to reduce the resistance impact on the effectiveness of various treatments. To conduct a time-trend analysis of resistance to antibiotics in Europe. The international prospective European Registry on Management (Hp-EuReg) collected data on all infected adult patients diagnosed with culture and antimicrobial susceptibility testing positive results that were registered at AEG-REDCap e-CRF until December 2020. : Overall, 41,562 patients were included in the Hp-EuReg. Culture and antimicrobial susceptibility testing were performed on gastric biopsies of 3974 (9.5%) patients, of whom 2852 (7%) were naive cases included for analysis. The number of positive cultures decreased by 35% from the period 2013-2016 to 2017-2020. Concerning naïve patients, no antibiotic resistance was found in 48% of the cases. The most frequent resistances were reported against metronidazole (30%), clarithromycin (25%), and levofloxacin (20%), whereas resistances to tetracycline and amoxicillin were below 1%. Dual and triple resistances were found in 13% and 6% of the cases, respectively. A decrease ( < 0.001) in the metronidazole resistance rate was observed between the 2013-2016 (33%) and 2017-2020 (24%) periods. : Culture and antimicrobial susceptibility testing for are scarcely performed (<10%) in Europe. In naïve patients, resistance to clarithromycin remained above 15% throughout the period 2013-2020 and resistance to levofloxacin, as well as dual or triple resistances, were high. A progressive decrease in metronidazole resistance was observed.
Lv Y, Li D, Zhang D, Chen S, Chen R, Wang Y Front Cell Infect Microbiol. 2025; 14:1505166.
PMID: 39742338 PMC: 11685075. DOI: 10.3389/fcimb.2024.1505166.
Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.
PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.
Alhijazien S, Daoud S, Alzayadi M, Al Sarhan M, Aldomi M, Al Shawabkeh T Cureus. 2024; 16(10):e72033.
PMID: 39569309 PMC: 11578150. DOI: 10.7759/cureus.72033.
Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance in in Serbia.
Kekic D, Jovicevic M, Kabic J, Lolic I, Gajic I, Stojkovic S Antibiotics (Basel). 2024; 13(10).
PMID: 39452199 PMC: 11505191. DOI: 10.3390/antibiotics13100933.
Clarithromycin sustained-release tablet may be an improper therapy for the eradication of .
Zuo X, Shen Q, Luo J, Wang Y, Zhao C Therap Adv Gastroenterol. 2024; 17:17562848241275332.
PMID: 39290332 PMC: 11406650. DOI: 10.1177/17562848241275332.